Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer

Abstract Background Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort ( n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1–42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9–not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. Methods Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. Results With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16–48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9–15.8), and median OS was 15.9 months (95% CI: 10.4–22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). Conclusions With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.

Authors

Institutions

Publication Details

Journal
International Journal of Clinical Oncology
Published
2026-11-14
DOI
https://doi.org/10.1007/s10147-026-03214-9
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer

Akihiko Shimomura, Yuki Iwahori, Nobuko Kawaguchi‐Sakita, J. Shao et al.
International Journal of Clinical Oncology
Breast Cancer Treatment Studies
article

Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer

Akihiko Shimomura, Yuki Iwahori, Nobuko Kawaguchi‐Sakita, J. Shao, Yoichi Naito, Takahiro Kogawa, Norikazu Masuda, Catherine Lai, T. Nakayama, Dianna Gary, Danh Huynh, Hiroji Iwata, Kazuki Sudo, Koji Matsumoto, Yutaka Yamamoto, Takanori Ishida
article en

Abstract

Abstract Background Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort ( n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1–42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9–not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. Methods Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. Results With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16–48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9–15.8), and median OS was 15.9 months (95% CI: 10.4–22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). Conclusions With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.

International Journal of Clinical Oncology
Nagoya City University (JP), Tohoku University Hospital (JP), National Center for Global Health and Medicine (JP), Kumamoto University Hospital (JP), The Cancer Institute Hospital (JP), Gilead Sciences (United States) (US), National Cancer Center Hospital East (JP), Kyoto University Hospital (JP), Osaka International Cancer Institute (JP), Hyogo Prefectural Cancer Center (JP), Japanese Foundation For Cancer Research (JP), Gilead Sciences (Japan) (JP), National Cancer Center Hospital (JP), Nagoya University (JP)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon